Natco Pharma Ltd
NSE: NATCOPHARM BSE: 524816
₹1022.35
(-1.62%)
Sat, 21 Mar 2026, 05:44 am
Market Cap186.18B
PE Ratio11.76
Dividend0.50
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1981
- Incorporated on September 19 as NATCO FINE PHARMACEUTICALS P. LTD.
1984
- Began operations manufacturing conventional and timed release dosage forms.
1985
- Pioneered Timed Release Technology with Multi-unit, Multi-layered System in India.
1986
- Awarded Import Substitution Award for Timed Release Technology.
1992
- Became deemed public company under Section 43A effective July 1.
1993
- Changed name to NATCO PHARMA LTD.
1995
- Merger of Natco Pharma, Natco Laboratories, Natco Parenterals, and Dr. Karanth Pharma Chemical Labs effective April 1.
1996
- Launched Suminat (Sumatriptan Succinate).
- Awarded export house status by Directorate General of Foreign Trade.
1997
- Entered agreement for product rights in Russia and CIS countries.
- Merged four group companies effective April 1, 1995.
1998
- Tied up with Mallinckrodt for naproxen exports.
2000
- Executive Director Dr. K.V. Ranga Rao resigned but continued as director.
2001
- Entered formulations segment with 34 products.
- Allotted 42,70,500 equity shares at Rs. 17 on preferential basis.
2002
- Received revamping package from IDBI.
- Dr. Mohana R Velagapudi, Dr. K V Ranga Rao, and Dr. N Ramakrishna Rao resigned from Board.
- Board approved preferential equity warrants and preference shares.
- Received TGA Australia approval for Mekaguda facility.
- Inducted Dr. K U Mada to Audit Committee and constituted Remuneration Committee.
2003
- Launched VEENAT (Imatinib 100 mg capsules).
- Launched Zoldonat (Zoledronic Acid injection).
- Launched Letronat 2.5 mg (Letrozole) tablets.
- Received Rs. 35 crore export order for citalopram hydrobromide and imatinib mesylate.
- Won DSIR National Award for R&D efforts.
- Appointed Rajeev Nannapaneni as Chief Operating Officer.
- Promoters offloaded shares.
- Launched Temonat (Temozolomide) for brain tumours.
- Launched GEFTINAT (Gefitinib 250 mg).
2004
- Demise of Board Director Mr. Raj Monani.
- Launched Ganciclovir 250 mg capsules and 500 ml injection.
- Established Oncology division with anti-cancer drug launch.
- Bagged award from Indian Red Cross Society Chennai.
- Launched drug for prostate cancer.
- Launched drug for ovarian cancer.
- Launched Curcumin 500 mg capsules under Turcumin.
2005
- Received Certification of Suitability from European Pharmacopoeia for Ondansetron Hydrochloride Dihydrate and Sumatriptan Succinate.
- Signed MoU for sharing oncology product technology.
- Launched anti-migraine drug.
- Tied up with Temple University, USA.
- Launched Vorizol.
2006
- Launched Pemnat (Pemetrexed) for non-small cell lung cancer.
2007
- Launched oral contraceptive Tarana.
2009
- Tied up with Dr. Reddy's for oncological products.
2010
- Launched BENDIT (Bendamustine).
- Launched Anastrazole in USA.
2011
- New chemical entity received Orphan designation from US FDA.
- Filed ANDA for generic Tykerb and tied up with Lupin Limited.
- Formed JV NATCOFARMA DO BRASIL with Levomed LLC for Brazil.
2012
- Won Golden Peacock Award for Corporate Social Responsibility.
- Received approval for Lansoprazole capsules.
2013
- Received marketing approval for Rizatriptan Benzoate ODT 5 mg and 10 mg tablets.
- Received US Court approval for generic Copaxone.
- Won cancer drug case.
2014
- Kothur Formulation Facility found acceptable by USFDA.
- Received USFDA approval for Oseltamivir Phosphate Capsules.
- Marketing partner Breckenridge filed ANDA for Everolimus 0.25 mg, 0.5 mg, 0.75 mg tablets.
2015
- Launched HEPCINAT LP in Nepal.
- Received Best Speciality Brand Silver Award for marketing excellence.
- Won Golden Peacock Innovation Management Award.
- Launched HEPCINAT, first generic Sofosbuvir (Sovaldi) in Nepal.
- Split face value from Rs. 10 to Rs. 2.
2016
- Launched first generic Tamiflu Capsules in US market.
2017
- Launched VELPANAT in Nepal, first generic Sofosbuvir/Velpatasvir.
- Won Golden Peacock Occupational Health and Safety Award.
- Partner Mylan won US District Court ruling on Copaxone 40 mg/mL patents.
- Launched POMALID, first generic pomalidomide capsules in India.
- Alliance partner Lupin received FDA approval for generic Lanthanum Carbonate Chewable Tablets.
- Won Golden Peacock Innovation Management Award.
- Marketing partner Mylan launched generic Glatiramer Acetate (20 mg/mL and 40 mg/mL) in US.
- Marketing partner Alvogen launched first generic oseltamivir phosphate powder for oral suspension in US.
- Launched TAFNAT, Tenofovir Alafenamide tablets for chronic hepatitis B in India.
- Chairman VC Nannapaneni won India's Greatest Brands and Leaders 2016-17 awards.
2018
- Launched fixed dose combination of Sofosbuvir-Daclatasvir for Hepatitis C in India.
- Launched generic Posaconazole Injection, first available in India.
- Launched first generic Teriflunomide under brand DENOPSY for Multiple Sclerosis in India.
- Announced USFDA filing for Sofosbuvir tablets 400 mg.
- USFDA inspected Mekaguda API facility with zero observations.
2019
- USFDA completed inspection of Mekaguda API facility.
- Marketing partner Alvogen received FDA approval for Nitroglycerin Sublingual Tablets.
- Alliance partner Lupin received FDA approval for generic Bosentan Tablets.
- NATCO and Alvogen filed ANDA for Ibrutinib Tablets for US market.
- Launched Valsartan-Sacubitril tablets under brand VALSAC in India.
2020
- Announced launch of Lapatinib Tablets for breast cancer in US.
- Supported Columbia University's clinical trial of chloroquine phosphate for Covid-19.
- Received establishment inspection report (EIR) for Kothur formulation facility.
- Vizag formulation facility received USFDA approval.
2021
- Launched Tipanat tablets in India for advanced colorectal and gastric cancer.
- Announced launch of 10mg strength Everolimus Tablets (generic for Afinitor) in US market.
- Natco Pharma (Canada) Inc. launched PrNAT-LENALIDOMIDE Capsules, first generic alternative to Revlimid.
- Received approval for Carfilzomib Vials ANDA (generic for KYPROLIS) in US market.
- Signed Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India.
- Received final approval for Everolimus tablets (generic for Afinitor) for US market.
2022
- Launched Chlorantraniliprole (CTPR) product NATGEN.
- Signed license agreement with Medicines Patent Pool, Switzerland.
- Awarded Corporate Governance Award.
- Completed acquisition of Dash Pharmaceuticals LLC.
2023
- Launched generic Pomalidomide Capsules in Canada.
- Received final approval for Tipiracil Hydrochloride and Trifluridine (generic for Lonsurf) for the US market.
2024
- Partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800